

Product Data Sheet

Ubrogepant

Cat. No.: HY-12366

CAS No.: 1374248-77-7 Molecular Formula: $C_{29}H_{26}F_3N_5O_3$ Molecular Weight: 549.54

Target: **CGRP Receptor**

Pathway: GPCR/G Protein; Neuronal Signaling

Powder

4°C 2 years

In solvent -80°C 6 months -20°C 1 month

-20°C

SOLVENT & SOLUBILITY

In Vitro

Storage:

DMSO: 250 mg/mL (454.93 mM; Need ultrasonic)

3 years

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.8197 mL	9.0985 mL	18.1970 mL
	5 mM	0.3639 mL	1.8197 mL	3.6394 mL
	10 mM	0.1820 mL	0.9099 mL	1.8197 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 6.25 mg/mL (11.37 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 6.25 mg/mL (11.37 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 5 mg/mL (9.10 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Ubrogepant (MK-1602) is an orally active calcitonin gene-related peptide receptor (CGRP) antagonist with potential for use
	in acute $migraine^{[1]}$.

MK-1602^[1] IC₅₀ & Target

REFERENCES

[1]. Li CC, et al. Population PK A Sampling. J Clin Pharmacol. 20			ist: Enriching In-Clinic Plasma PK Sampling V	With Outpatient Dried Blood Spot
	Cautian Duadwathaa		adiaal amuliaatiana Fannaaanah waa an	I
			edical applications. For research use on	
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExpress.co outh Junction, NJ 08852, USA	om
	Addiess. I	beer rank bi, saite Q, Moillin	outil sufficient, NS 00032, OSA	

Page 2 of 2 www.MedChemExpress.com